Sareum Holdings PLC Sierra Oncology Granted US and EU Patents
May 31 2017 - 1:01AM
RNS Non-Regulatory
TIDMSAR
Sareum Holdings PLC
31 May 2017
(AIM: SAR) 31 May 2017
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sierra Oncology Granted US and EU Patents for Chk1 inhibitor
SRA737
Sareum Holdings plc (AIM:SAR), the specialist cancer drug
discovery and development company, notes an announcement made by
Sierra Oncology, Inc. yesterday stating that selection patents(*)
that explicitly protect the Chk1 inhibitor SRA737 have been granted
in the USA and Europe, extending its protection period to the year
2033 in the US.
The full announcement can be found on Sierra Oncology's IR
website(**) .
Dr Tim Mitchell, CEO of Sareum, commented: "SRA737 is a valuable
asset to Sareum through its licence to Sierra Oncology. We are
pleased to see that patents to protect it have been granted in
these major territories."
Sierra Oncology holds exclusive and worldwide rights for the
Chk1 inhibitor, SRA737, having licensed the programme from Sareum's
co-investment partner, the CRT Pioneer Fund in September 2016. This
announcement does not trigger any milestone payments under the
terms of the agreement.
* Patent nos US 9,663,503, EU 2855448
**http://investor.sierraoncology.com/2017-05-30-Sierra-Oncology-Granted-US-and-EU-Patents-for-Chk1-inhibitor-SRA737
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / Nick Prowting 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
The Communications Portfolio
(Sareum Media enquiries)
Ariane Comstive
Ariane.comstive@communications-portfolio.co.uk 07785 922 354
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAMMITMBAJBLR
(END) Dow Jones Newswires
May 31, 2017 02:01 ET (06:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024